These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36314537)

  • 1. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Tichenor MS; Wiener JJM; Rao NL; Bacani GM; Wei J; Pooley Deckhut C; Barbay JK; Kreutter KD; Chang L; Clancy KW; Murrey HE; Wang W; Ahn K; Huber M; Rex E; Coe KJ; Wu J; Rui H; Sepassi K; Gaudiano M; Bekkers M; Cornelissen I; Packman K; Seierstad M; Xiouras C; Bembenek SD; Alexander R; Milligan C; Balasubramanian S; Lebsack AD; Venable JD; Philippar U; Edwards JP; Hirst G
    J Med Chem; 2022 Nov; 65(21):14326-14336. PubMed ID: 36314537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
    Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.
    Guo Y; Hu N; Liu Y; Zhang W; Yu D; Shi G; Zhang B; Yin L; Wei M; Yuan X; Luo L; Wang F; Song X; Xin L; Wei Q; Li Y; Guo Y; Chen S; Zhang T; Zhang S; Zhou X; Zhang C; Su D; Liu J; Cheng Z; Zhang J; Xing H; Sun H; Li X; Zhao Y; He M; Wu Y; Guo Y; Sun X; Tian A; Zhou C; Young S; Liu X; Wang L; Wang Z
    J Med Chem; 2023 Mar; 66(6):4025-4044. PubMed ID: 36912866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
    Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
    J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
    J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis.
    Fang X; Liu C; Zhang K; Yang W; Wu Z; Shen S; Ma Y; Lu X; Chen Y; Lu T; Hu Q; Jiang Y
    Eur J Med Chem; 2023 Jan; 246():114940. PubMed ID: 36462441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
    Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
    J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
    Robbins DW; Noviski MA; Tan YS; Konst ZA; Kelly A; Auger P; Brathaban N; Cass R; Chan ML; Cherala G; Clifton MC; Gajewski S; Ingallinera TG; Karr D; Kato D; Ma J; McKinnell J; McIntosh J; Mihalic J; Murphy B; Panga JR; Peng G; Powers J; Perez L; Rountree R; Tenn-McClellan A; Sands AT; Weiss DR; Wu J; Ye J; Guiducci C; Hansen G; Cohen F
    J Med Chem; 2024 Feb; 67(4):2321-2336. PubMed ID: 38300987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation.
    Goess C; Harris CM; Murdock S; McCarthy RW; Sampson E; Twomey R; Mathieu S; Mario R; Perham M; Goedken ER; Long AJ
    Mod Rheumatol; 2019 May; 29(3):510-522. PubMed ID: 29862859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
    Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
    Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
    Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
    Lin P; Zhang D; Lin J
    Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
    Owens TD; Brameld KA; Verner EJ; Ton T; Li X; Zhu J; Masjedizadeh MR; Bradshaw JM; Hill RJ; Tam D; Bisconte A; Kim EO; Francesco M; Xing Y; Shu J; Karr D; LaStant J; Finkle D; Loewenstein N; Haberstock-Debic H; Taylor MJ; Nunn P; Langrish CL; Goldstein DM
    J Med Chem; 2022 Apr; 65(7):5300-5316. PubMed ID: 35302767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
    Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
    Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.